A study of 2,646 Swedish psoriasis patients receiving systemic therapy for their condition, conducted at Umeå University, Sweden, and the...

In three phase III trials, ixekizumab—a monoclonal antibody against interleukin-17A—was superior to placebo in the treatment of...